Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775504 | 0.83 | HRH3 (0.40) | SLC6A4HRH3 | |
| SCHEMBL4104900 | 0.76 | JAK2 (0.50) | SLC6A4HRH3NPC1KDM4EALDH1A1 | |
| SCHEMBL24774474 | 0.71 | SIGMAR1 (0.37) | KDM4EKMT2A | |
| SCHEMBL5327778 | 0.70 | KDM4E (0.53) | SLC6A4HRH3NPC1KDM4EALDH1A1 | |
| SCHEMBL24775499 | 0.70 | OPRM1 (0.42) | — | |
| SCHEMBL24774530 | 0.70 | ACHE (0.36) | — | |
| SCHEMBL24774477 | 0.70 | OPRM1 (0.42) | — | |
| SCHEMBL24774489 | 0.70 | TMEM97 (0.43) | — | |
| SCHEMBL5344927 | 0.69 | KDM4E (0.52) | SLC6A4HRH3NPC1KDM4EALDH1A1 | |
| SCHEMBL5070782 | 0.69 | PSEN1 (0.55) | HRH3NPC1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SLC6A4 4836/4885HRH3 4417/4885NPC1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.